TIDES USA 2025
TIDES USA 2025 is scheduled for May 19-22, 2025, at the Manchester Grand Hyatt in San Diego, California. This premier event focuses on accelerating oligonucleotide and peptide innovations through collaborative discovery, development, and commercialization. The conference will feature over 200 presentations across six concurrent tracks, covering topics such as oligonucleotides, peptides, mRNA, genome editing, and drug delivery. Additionally, eight workshops are planned to provide in-depth insights into specific areas.
Attending TIDES USA 2025 offers a multitude of benefits for professionals in the oligonucleotide and peptide therapeutics field.
Why you should consider participating:
- Cross-Industry Innovation Exchange
Engage with experts across various disciplines to foster discussions that challenge conventional thinking and lead to groundbreaking solutions in therapeutic development. This collaborative environment encourages the exchange of diverse ideas, accelerating innovation.
- Expert Scientific Content
Gain direct access to renowned scientists who can provide valuable insights into your specific challenges. These focused interactions offer unique opportunities to refine your research approaches and overcome technical obstacles, enhancing your scientific endeavors.
- Research Showcase Opportunity
Present your latest scientific breakthroughs through the poster presentation program. Your work will be prominently displayed in both the physical exhibit hall and the digital ConnectMe platform, maximizing visibility to potential collaborators and industry leaders.
- Advanced Technology Showcase
Explore the latest technological innovations in the comprehensive exhibit hall. Discover cutting-edge tools and solutions that could revolutionize your research and development processes, keeping you at the forefront of technological advancements.
- Life Sciences Hub: San Diego
With over 1,200 biotech companies and year-round favorable weather, San Diego provides an energizing setting for scientific collaboration and networking. The city's thriving life sciences community offers ample opportunities for professional growth and partnership.
- Digital Conference Enhancement
Enhance your conference experience with the ConnectMe app, featuring the agenda, attendee list, matchmaking capabilities, and seamless scheduling tools. Stay connected with real-time updates and efficiently manage your networking opportunities through this integrated digital platform.
Registration
Attendees are encouraged to register by March 21, 2025, to save up to $400 on conference fees.
Registration fees
Industry Rate
- Main Conference Pass + Recordings and Workshop Pass + Recordings [May 19-22]: $4,499.00
- Main Conference Pass + Recordings [May 20-22]: $3,699.00
Academic or Government Rate
- Main Conference Pass + Recordings and Workshop Pass + Recordings [May 19-22]: $1,649.00
- Main Conference Pass + Recordings [May 20-22]: $1,129.00
Main Conference Pass + Recordings and Workshop Pass + Recordings [May 19-22] include:
- Pre-conference workshops on May 19
- All main conference sessions across all tracks from world-renowned speakers May 20-22.
- Pre-conference workshop on-demand sessions recordings for 1 year after the event pending speaker approval
- Main conference on-demand sessions recordings for 1 year after the event pending speaker approval
- 2 Live Streamed Tracks: ONLY the oligonucleotide tracks will be live streamed
- Speaker presentation slides pending speaker approval
- Exhibition Hall featuring 75+ live booths in the exhibit hall during May 20-22
- Live poster presentations in poster hall
- Networking opportunities: daily networking lunches and refreshment breaks during and digital networking opportunities throughout the event
- Virtual exhibit and poster hall which consists of a majority of vendors and poster presenters from live event
- The full attendee list, both live and digital only attendees, with capability to video chat, instant message and request meetings
Main Conference Pass + Recordings [May 20-22] include:
- All main conference sessions across all tracks from world-renowned speakers May 20-22.
- Main conference on-demand sessions recordings for 1 year after the event pending speaker approval
- 2 Live Streamed Tracks: ONLY the oligonucleotide tracks will be live streamed
- Speaker presentation slides pending speaker approval
- Exhibition Hall featuring 75+ live booths in the exhibit hall during May 20-22
- Live poster presentations in poster hall
- Networking opportunities: daily networking lunches and refreshment breaks during and digital networking opportunities throughout the event
- Virtual exhibit and poster hall which consists of a majority of vendors and poster presenters from live event
- The full attendee list, both live and digital only attendees, with capability to video chat, instant message and request meetings
Key Dates:
- Early Registration Deadline: March 21, 2025
- Poster Abstract Submission Deadline: April 18, 2025
- Poster PDF Submission Deadline: May 2, 2025
Abstract Submission
Poster Presentations
How to Present a Scientific Poster at TIDES USA 2025
- Step 1: Register for a Main Conference Pass or Main Conference + Workshop Pass and select the Scientific Poster Presentation add on option
- Step 2: Our team will send you a link to submit your poster abstract, which must be submitted by April 18th, 2025
- Step 3: A poster coordinator will follow up with print and digital specifications once the abstract is received. Submit the PDF of your poster by May 2nd, 2025
Program
The agenda is available! You can download an Agenda using this link.
Key Sessions - Tuesday, May 20, 2025
8:15 AM - 9:00 AM The Science Behind the GLP-1 Medicines: A Historic View and Future Outlook
Glucagon-Like Peptide-1 receptor agonists (GLP-1RAs), such as liraglutide and semaglutide, offer diverse biological applications and are sanctioned for treating diabetes with established cardiovascular benefits, encompassing stroke prevention, and obesity management. Physiologically, GLP-1 plays a crucial role in glucose equilibrium, appetite control, and various other functions. Notably, long-acting pharmacological agents are pivotal for treatment success. These GLP-1RAs influence weight loss, potentially through brain GLP-1R-mediated mechanisms, and also demonstrate promise in mitigating systemic inflammation. Ongoing research is exploring their potential in addressing liver disease and Alzheimer's disease. This underscores the wide-ranging impact of GLP-1 physiology in various clinical domains.
- Lotte Bjerre Knudsen, PhD, Chief Scientific Advisor & Head of GLP-1 CoE, Novo Nordisk A/S
9:00 AM - 9:45 AM “I Love Conjugates”: The GalNAc Revolution and Its Impact on Oligonucleotide Therapeutic Development
Delivery, Delivery, Delivery. This presentation will provide insights into the science of GalNAc conjugates and current proven applications for siRNAs & ASOs and other emerging modalities within RNAi. Insights into other conjugates like lipidic nucleic acids, as well as the promise of other ligands will be discussed, along with future challenges and opportunities of this exciting technology.
- Muthiah (Mano) Manoharan, PhD, Senior Vice President of Drug Innovation and Distinguished Research Scientist, Alnylam Pharmaceuticals
10:15 AM - 11:00 AM Realizing the Promise of CRISPR Therapeutics
Intellia Therapeutics is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. Our in vivo programs use IV administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to engineer human T cells to treat cancer and autoimmune diseases. Preclinical and clinical data will be discussed.
- Kristy Wood, PhD, SVP, Technical Operations, Intellia Therapeutics
11:00 AM - 11:45 AM Oligonucleotide Therapeutics: Current Challenges and Opportunities
Until 2016, oligonucleotide therapeutics was characterized by strong science but weak commercial success. Since 2016, commercial success with compounds that have major positive impacts on patient lives have become routine outcomes. Success, however, should not lead to complacency. Rigorous experimental design at the interface of chemistry and biology will remain central to strong development programs. This talk will discuss the state of the field and what to look for when evaluating research projects.
- Dr. David Corey, PhD, Professor of Pharmacology and Biochemistry at UT Southwestern; Past President, OTS
13:00 - 13:45 State of the Art: A Look at Oligonucleotide Therapeutics Past, Present, and Future
In three decades, I have watched as oligonucleotide therapeutics progressed from a niche technology into a mainstream modality. This evolution of oligonucleotide therapeutics was propelled by advances in several critical areas including, chemistry and synthesis, a deeper understanding of biological mechanisms, innovative delivery strategies, and novel business models. The continued transformation of the field will be informed by established knowledge, utilization of new technologies including machine learning, as well as the perspectives of patient communities we serve.
- Art Levin, PhD, Retired CSO at Avidity Biosciences
13:45 - 14:30 Clinical Update on Oligonucleotides for Cardiovascular Disease
- Sam Tsimikas, MD, Senior Vice President of Global Cardiovascular Development at Ionis Pharmaceuticals
15:30 - 16:15 RaPID Display and Selection of Pseudo-natural Products
This lecture discusses a new development of display format for the discovery of pseudo-natural products against intracellular targets of protein. The technology enables us to access unexplored chemical space with cell membrane permeability of macrocycles.
- Hiroaki Suga, PhD, Professor of Chemistry, School of Science at University of Tokyo
16:15 - 17:00 Addressing the Challenges of Bringing New Therapeutic Modalities to Market: Technical and Regulatory Considerations
- Rachael Anatol, Deputy Super Office Director, Office of Therapeutic Products, CBER at FDA
Workshops
Pre-Conference Workshops - Monday, May 19, 2025
Morning Workshops (9:00 AM - 12:30 PM)
Workshop AM1: Introduction to Therapeutic Oligonucleotides - Design, Function, and Delivery
- This workshop provides an overview of therapeutic oligonucleotides, including their design, mechanisms of action, and delivery strategies.
Workshop AM2: Novel Paradigms for the Manufacture of Synthetic Oligonucleotides, Regulatory Strategies, and Controls
- Focuses on innovative manufacturing processes, regulatory considerations, and quality control measures for synthetic oligonucleotides.
Workshop AM3: Introduction to Genome Editing and Delivery
- Covers the fundamentals of genome editing technologies and their delivery methods, emphasizing therapeutic applications.
Workshop AM4: Translational Strategies to Accelerate Peptides to the Clinic
- Discusses approaches to expedite the clinical development of peptide therapeutics, bridging the gap between research and clinical application.
Afternoon Workshops (1:30 PM - 5:00 PM)
Workshop PM1: Leveraging Artificial Intelligence (AI) & Machine Learning (ML) in Drug Design and Development
- Explores the integration of AI and ML in drug discovery and development, highlighting how these technologies enhance efficiency and innovation.
Workshop PM2: Introduction to Analytical Control Strategies for Therapeutic Oligonucleotides
- Focuses on analytical methodologies and control strategies essential for the development and quality assurance of therapeutic oligonucleotides.
Workshop PM3: Next-Gen Quality Control: Advancements in Oligonucleotide Analysis and Testing
- Highlights the latest advancements in quality control practices, specifically in the analysis and testing of oligonucleotide therapeutics.
Workshop PM4: Sustainable Manufacturing: Continuous Processing and Green Chemistry
- Examines sustainable manufacturing practices, including continuous processing techniques and green chemistry principles, aimed at reducing environmental impact in therapeutic production.
Venue
Manchester Grand Hyatt San Diego
1 Market Place
San Diego, California 92101 United States
Phone: +1 619 232 1234
